Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 2Carcinoma 2Urinary Incontinence 1Squamous Cell Carcinoma of Head and Neck 1Pyridoxine-dependent epilepsy 1Prostatic Neoplasms 1Peripheral Nervous System Diseases 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Neurotoxicity Syndromes 1Neoplasms 1Neoplasm Metastasis 1Mouth Neoplasms 1Liver Neoplasms 1Head and Neck Neoplasms 1Gastric Adenocarcinoma 1Esophageal Neoplasms 1Erectile Dysfunction 1Colorectal Neoplasms 1Carcinoma, Hepatocellular 1Adenocarcinoma 1

Interventions

apatinib 2Hyperthermic Intraperitoneal Chemotherapy 2Gastrectomy 2trastuzumab deruxtecan 1taxane 1sintilimab 1pembrolizumab 1durvalumab 1disitamab vedotin 1cabozantinib 1Taxes 1Tadalafil 1SHR-1701 1S 1 (combination) 1Platinum 1Paclitaxel 1Oxaliplatin 1Magnetic Resonance Spectroscopy 1Indocyanine Green 1Immunotherapy, Adoptive 1Cytoreduction Surgical Procedures 1Cisplatin 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Gastric Adenocarcinoma × Tadalafil × 1 year × Clear all
NCT05709574 2025-10-16

Tadalafil Effect + Chemotherapy in Resectable Gastric/GEJ Cancer

University of Arizona

Phase 2 Recruiting
10 enrolled
Gastrointestinal

Gastric Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡